"rationale","uuid:ID","id","instanceType","versionIdentifier"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","8be97a91-d06c-4886-886b-f993a3808aa6","StudyVersion_1","StudyVersion","2"
